R eaders of this column are familiar with my interest in age-management medicine. Good science has shown the benefit of the consumption of various vitamins, minerals, antio xidants, and plant extract supplements, and the maintenance of hormones at their optimal, youthful levels for the promotion of health and longevity. My goal is not just an increased lifespan, but an increased "healthspan," free of disabling physical and mental conditions. Patients who come to us seeking cosmetic improvement are frequently interested in antiaging strategies. I recommend that physicians and patients alike read Life Extension magazine for its wealth of information on these matters.
This writing concerns the prostate. Prostate cancer is the most common internal cancer of men. Autopsy evidence shows cancer cells in 34 % of men aged 40-49 and as many as 70% of men 80 and older. 1.2 Fortunately, most of these men do not develop clinical prostate cancer, but the lifetime risk of this cancer may be as high as I in 7.
Prostate-specific antigen (PSA) is the protein in highest concentration in the prostate gland and is used for screening testing for prostate enlargement, cancer, and inflammation. Evidence is accumulating indicating that PSA itself may be active in the process of cancer development and metastases. 3 -5 In the absence of a strong family history, current recommendations are that men begin PSA testing at age 50 and be tested annually thereafter. But the upward trend of PSA is important as well as is the exact number. An increase of 2 ng/ml. may be an indicator of early prostate cancer. 219 James B. Bridenstine , MD Editor-in-Chief Therefore, it seems to be wise for men to have their first PSA screenings at age 35, when values are likely in their lower range , and then to chart the progression of PSA with repeat testing annually.?
Certain nutrients have been shown to shrink benign prostatic hypertrophy (BPH) and tumors. Lycopene in dosages of 4-10 mg/day causes significant reduction of PSA (many times to below 4 ng/mL) in prostate cancer patients, as well as stabilization or reduction of tumor load. 7 ,8 In a mouse model, boric acid highly reduced PSA and significantly reduced tumor size." Both androgen-dependent and androgen-independent human prostate cancer cell lines are inhibited by boric acid. 10 Because boron consumption correlates with reduced prostate cancer risk,II daily ingestion of 6-15 mg may become a cost-effective adjuvant therapy. Another mineral, selenium, has been shown to help prostate cancer cells overcome their resistance to programmed cell death (apoptosis).' "
The green tea flavonoid epigallocatechin gallate restrains PSA expression as well as inhibiting certain tumor-promoting activities.l ' Men who consume diets higher in soy seem to have a lower frequency of prostate cancer and a reduced progression of the disease. 14 Curcumin, the yellow pigment found in the spice turmeric, has been shown to inhibit prostate cancer cell growth and induce apoptosis,15,1 6 make the cells less likely to metastasize to bone,17 and sensitize them to radiation therapy. 18 Coenzyme Q I 0 placed in cell cultures for 48 hours has been shown to inhibit by 70% the growth of the most common prostate cancer cell line, P3, 1 9 A variety of plant extracts have been available in Europe (and more recently in the US) to treat BPH, including saw palmetto, pygeum, and nettle root (http:// www.lef.org). Although not widely used in the US, a plant lipid, beta-sitosterol, has been extensively used for decades in Europe to reduce BPH?O Beta-sitosterol inhibits prostate cancer celllines,21,22 as does the combination of resveratrol (a polyphenol in grapes and red wine) and beta-sitosterol. 23
The above dietary supplements are easy to incorporate into one's daily regimen. By maintaining a lean body weight, exercising regularly, following a low-glycemicindex diet to control insulin, and taking fish oil and other vitamins, minerals, and supplements, one can reduce one's risk of heart disease, stroke, diabetes, cancer, dementia, and other so-called diseases of aging. 
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